TORONTO, Oct. 18, 2016 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced the appointment of Dr. Richard Gregory to its Board of Directors.
"Doctor Gregory brings a wealth of outstanding and highly relevant research and development (R&D) experience to our Board of Directors," said ProMIS Executive Chairman Eugene Williams. "His broad experience in immune-related therapies and drug development will provide valuable insight as we continue to progress our programs in Alzheimer's and ALS."
Richard Gregory, Ph.D., is currently Chief Scientific Officer and Executive VP of Research at Immunogen. Prior to this role, he held several senior leadership positions in R&D at Genzyme and Sanofi-Genzyme.
"I am delighted to join the Board of Directors of ProMIS Neurosciences," stated Dr. Gregory. "The Company's innovative, precision medicine approach to Alzheimer's disease and ALS offers great hope for addressing these urgent medical challenges and I look forward to supporting these important efforts."
About Richard Gregory, P.h.D.
Richard Gregory, Ph.D., joined ImmunoGen as Chief Scientific Officer and Executive VP of Research in January of 2015. In this role, he provides leadership and direction to the research organization and is responsible for the generation of development candidates based upon ImmunoGen's Antibody Drug Conjugate technology. Prior to ImmunoGen, Richard held a variety of positions at Genzyme and Sanofi-Genzyme, including Vice President of Gene Therapy, Head of Corporate Research and Head of R&D for the Sanofi/Genzyme R&D Center. Dr. Gregory received his B.Sc. in Biochemistry from Virginia Tech, his Ph.D. in Biochemistry from the University of Massachusetts, and did his post-doctoral training in cancer genetics at the Worcester Foundation for Experimental Biology. He is the co-author of more than 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology. Dr. Gregory is a Fellow of the American Institute for Medical and Biological Engineering.
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences aims to develop novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please consult the Company's website at: www.promisneurosciences.com
SOURCE ProMIS Neurosciences Inc.
For further information: NATIONAL Equicom: Michael Moore, Tel. 858-886-7813, [email protected]; Abby Garfunkel, Tel. 403-218-2887, [email protected] or contact Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, [email protected]